GALECTIN-3 AND NT-proBNP AS BIOMARKERS OF HEART FAILURE DECOMPENSATION

GALECTIN-3 AND NT-proBNP AS BIOMARKERS OF HEART FAILURE DECOMPENSATION

Aim. To compare the levels of galectin-3 and N-terminal brain natriuretic peptide precursor (NT-proBNP) in heart failure patients with saved ejection fraction of the left ventricle (HF-sEF) and heart failure with low ejection fraction (HF-lEF). To study the possibilities for implementation of galect...

Full description

Bibliographic Details
Main Authors:	Yu. V. Dubolazova, O. M. Drapkina
Format:	Article
Language:	Russian
Published:	«FIRMA «SILICEA» LLC 2017-02-01
Series:	Российский кардиологический журнал
Subjects:	heart failure with normal ejection fraction nt-probnp galectin-3 biomarkers of heart failure
Online Access:	https://russjcardiol.elpub.ru/jour/article/view/829

Similar Items

Vericiguat and NT‐proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial
by: Michele Senni, et al.
Published: (2022-12-01)

Relationship between NT-proBNP and the ejection fraction during intensive care variety in polytrauma patients with concomitant cardiac disorder
by: Svitlana Lutska, et al.
Published: (2021-10-01)

The importance of NT proBNP in hypertensive patients management for preventing heart failure
by: Irina Cuciureanu, et al.
Published: (2021-03-01)

Value of NT-proBNP and Galectin-3 as Biomarkers in the Follow-Up of Asymptomatic Elderly Patients with Severe Aortic Stenosis
by: Mónica Ramos, et al.
Published: (2023-04-01)

Performance of the Abbott Architect Immuno-Chemiluminometric NT-proBNP Assay
by: Chin-Shern Lau, et al.
Published: (2022-05-01)

SST2 and NT-proBNP biomarkers in prediction of COVID-19
by: O.O. Samchuk, et al.
Published: (2023-06-01)

Serum level of apelin-13 negatively correlated with NT-proBNP in heart failure patients
by: Goidescu Cerasela Mihaela, et al.
Published: (2016-12-01)

The Potential Role of Salivary NT-proBNP in Heart Failure
by: Aidonis Rammos, et al.
Published: (2023-08-01)

Evaluation of Galectin-3 as a Novel Diagnostic Biomarker in Patients with Heart Failure with Preserved Ejection Fraction
by: Jyothirmayi Kanukurti, et al.
Published: (2020-08-01)

Determining the role of NT-proBNP levels in diabetic patients with heart failure: A study from North India
by: Merajul H Siddiqui, et al.
Published: (2024-01-01)

Correlation of NT-proBNP levels with clinical and echocardiographic features in evaluation of patients admitted with heart failure
by: Dhinakaran K, et al.
Published: (2023-12-01)

Prognostic value of pathogenetic therapy-induced changes in NT-proBNP in patients with chronic heart failure
by: E M Mezhonov, et al.
Published: (2012-09-01)

Prognostic value of the combination of uric acid and NT-proBNP in patients with chronic heart failure
by: Gülsüm Meral Yılmaz Öztekin, et al.
Published: (2022-05-01)

Prognostic of NT-proBNP in heart failure patients with preserved, mid and reduced ejection fraction
by: Reynie Leonel Reinoso Gonella, et al.
Published: (2021-10-01)

Towards Point-of-Care Heart Failure Diagnostic Platforms: BNP and NT-proBNP Biosensors
by: Hussein Alawieh, et al.
Published: (2019-11-01)

Importance of NT-pro BNP in the Prevention of Heart Failure, Left Ventricular Systolic Dysfunction and Cardiovascular Events
by: Irina CUCIUREANU, et al.
Published: (2021-06-01)

Relationships between the activity of neurohormonal systems and intracardiac hemodynamics in patients with heart failure: focus on galectin-3
by: V. I. Podzolkov, et al.
Published: (2022-05-01)

Dynamics of NT-proBNP and ST2 levels as markers of heart failure in patients with endogenous Cushing syndrome (hypercortisolism)
by: Raisa S. Kosharnaia, et al.
Published: (2023-01-01)

Evaluation of NT-proBNP in children with heart failure younger than 3 years old
by: Iacob Daniela, et al.
Published: (2017-06-01)

Correlation between NT-proBNP plasma levels with mitral annular Tissue Doppler Velocities in Heart Failure patients
by: Raja Adil C Siregar, et al.
Published: (2013-06-01)

The Effect of Maximal and Submaximal Exercise Testing on NT-proBNP Levels in Patients with Systolic Heart Failure
by: Zdrenghea Dumitru Tudor, et al.
Published: (2014-03-01)

Time course of changes in the level of N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients with rheumatoid arthritis during therapy with an interleukin-6 receptor inhibitor
by: E. V. Gerasimova, et al.
Published: (2019-11-01)

The cost‐effectiveness of NT‐proBNP for assessment of suspected acute heart failure in the emergency department
by: Ryan Walkley, et al.
Published: (2023-12-01)

NT-proBNP LEVEL CHANGES AFTER COMBINATION THERAPY WITH BISOPROLOL AND ACE-INHIBITOR IN PATIENT WITH HEART FAILURE
by: Reine Risa Risthanti, et al.
Published: (2017-08-01)

ANALYSIS OF CHANGE IN NT-proBNP AFTER ANGIOTENSIN RECEPTOR BLOCKER (ARB) THERAPY IN PATIENT WITH HEART FAILURE
by: Intan Kusuma Dewi, et al.
Published: (2017-08-01)

Relationship Between Prohormone Brain Natriuretic Peptide (NT-proBNP) Level and Severity of Pulmonary Dysfunction in Patients With Chronic Congestive Heart Failure
by: Nazemiyeh Masoud, et al.
Published: (2015-03-01)

NT-proBNP independently predicts long term mortality after acute exacerbation of COPD – a prospective cohort study
by: Høiseth Arne, et al.
Published: (2012-10-01)

CLINICAL VALUE OF DETERMINING GALECTIN-3 IN PATIENTS WITH CHRONIC HEART FAILURE
by: K. A. Gyamdzhyan, et al.
Published: (2017-12-01)

Role of NT-proBNP and lung ultrasound in diagnosing and classifying heart failure in a hospitalized oldest-old population: a cross-sectional study
by: Matteo Landolfo, et al.
Published: (2024-04-01)

Development of a Rapid Diagnostic Kit for Congestive Heart Failure Using Recombinant NT-proBNP Antigen
by: Young-Ki Lee, et al.
Published: (2021-07-01)

ANALYSIS OF CHANGES IN THE SERUM LEVEL NT-proBNP AFTER ACE INHIBITORS THERAPY IN PATIENTS WITH HEART FAILURE
by: Halla Hisan Hartoto, et al.
Published: (2017-08-01)

NT-proBNP as a neuroendocrine tumor biomarker: beyond heart failure
by: Paweł Komarnicki, et al.
Published: (2023-09-01)

ProBNP for stratifying patients with heart failure
by: Antonio Carlos Pereira-Barretto, et al.
Published: (2003-09-01)

Assessment of the impact of different N terminal pro brain natriuretic peptide thresholds on echocardiography services
by: Eric Yii, et al.
Published: (2022-02-01)

NT‐proBNP as a Mediator of the Racial Difference in Incident Atrial Fibrillation and Heart Failure
by: Isaac R. Whitman, et al.
Published: (2019-04-01)

NT‐proBNP/BNP ratio for prognostication in European Caucasian patients enrolled in a heart failure prevention programme
by: Claire Sweeney, et al.
Published: (2021-12-01)

Correlation between plasma proBNP, echocardiographic and clinical parameters in patientswith type 2 diabetes mellitus
by: Irina Arkad'evna Bondar', et al.
Published: (2013-03-01)

Elevated Serotonin and NT-proBNP Levels Predict and Detect Carcinoid Heart Disease in a Large Validation Study
by: Sonja Levy, et al.
Published: (2022-05-01)

Prediction of clinical outcome in patients treated with cardiac resynchronization therapy - the role of NT-ProBNP and a combined response score
by: Z. Bakos, et al.
Published: (2018-04-01)

Ultra-Sensitive NT-proBNP Quantification for Early Detection of Risk Factors Leading to Heart Failure
by: Keum-Soo Song, et al.
Published: (2017-09-01)